Romosozumab, a dual-acting drug that increases bone formation and decreases resorption, received FDA approval. Rheumatologist Chad Deal, MD, discusses the related clinical trials and which patients make good candidates for this medication.
Patients Will Soon Have an Additional Option When New Osteoporosis Treatment Hits Market
Romosozumab-aqqg may give postmenopausal women an additional option for osteoporosis treatment when other medications are contraindicated. Women’s health specialist Holly Thacker, MD, explains the benefits and potential risks of this new regimen.